Campylobacter spp.* * (One weekly isolate from stewide convenience sample tested at CDC). Salmonella spp. (non-typhoidal) (~10% sample of statewide isolates tested at CDC). Shigella sonnei (All available statewide isolates tested at GPHL). Shigella flexneri (All available statewide isolates tested at GPHL). E. coli O157 (All available statewide isolates tested at CDC). Streptococcus pneumoniae (All invasive isolates from Atlanta (20-cty) MSA tested at CDC). Mycobacterium tuberculosis (All statewide isolates tested at GPHL). Antimicrobial Susceptibilities of Selected Pathogens, 2001 B-lactam antibiotics Number tested 53 185 406 47 27 665 428 Total isolates 640 1721 629 70 45 746 452 Percent Tested (%) 8 11 65 67 60 89 95 % Susceptible amoxicillin 89 amoxicillin-clavulanic acid 98 47 26 100 ampicillin 87 4 15 96 cefotaxime 83 cefoxitin >99 100 ceftiofur >99 100 ceftriaxone >99 >99 100 100 cefuroxime sodium 72 cephalothin >99 32 81 100 imipenem 100 100 meropenem 78 penicillin 68 azithromycin 96 erythromycin 96 73 nalidixic acid 74 99 >99 96 ciprofloxacin 74 100 >99 98 100 levofloxacin 99 amikacin 100 100 gentamicin chloramphenicol clindamycin 100 98 >99 98 100 100 90 96 32 100 96 96 94 apramycin 100 100 kanamycin 94 100 streptomycin 83 58 2 100 tetracycline 66 82 79 9 90 sulfamethoxazole 85 79 45 100 trimethoprim/sulfamethoxazole 98 83 60 100 62 vancomycin 100 ethambutol 99 isoniazid 94 rifampin >99 99 other antibiotics Trends, Comments and Other Pathogens Campylobacter Susceptibilities were determined using 2001 NCCLS breakpoints for Enterobacteriaceae. Erythromycin susceptible: MIC < 4 spp. g/ml. Salmonella spp. Antimicrobial treatment for enteric salmonellosis generally is not recommended. Antimicrobial resistance in S. sonnei is dynamic. In 2000, nearly half of isolates were resistant to trimethoprimShigella sonnei sulfamethoxazole (SXT). In 2001 this changed, with large outbreaks among children caused by a strain with SXT- susceptibility. Shigella flexneri E. coli O157 S. flexneri has been associated with outbreaks among men who have sex with men. Use of antimicrobials is controversial for enteritis caused by E. col i O157. Several studies have shown no symptomatic improvement and increased risk for hemolytic-uremic syndrome among treated patients (Guerrant RL et. al. Clin Infect Dis 2001; 32:331-51). Streptococcus Pneumoniae NCCLS 2001 MIC interpretive standards for S. pneumoniae were used for all antimicrobials. For penicillin, 16% (109/665) had intermediate susceptibility and 16% (106/665) were resistant (penicillin MIC breakpoints: susceptible <0.06 g/ml, intermediate 0.12-1 g/ml, resistant >2 g/ml). For amoxicillin, 6% (37/665) were intermediate and 5% (34/665) were resistant (amoxicillin MIC breakpoints: susceptible <2 g/ml, intermediate 4 g/ml, resistant >8 g/ml). For cefuroxime, <1% (1/665) were intermediate and 28% (184/665) were resistant (cefuroxime MIC breakpoints: susceptible <0.5 g/ml, intermediate 1 g/ml, resistant >2 g/ml). For cefotaxime, 14% (94/665) were intermediate and 3% (22/665) were resistant (cefotaxime MIC breakpoints: susceptible <0.5 g/ml, intermediate 1 g/ml, resistant >2 g/ml). For meropenem, 10% (68/665) were intermediate and 12% (78/665) were resistant (meropenem MIC breakpoints: susceptible <0.25 g/ml, intermediate 0.5 g/ml, resistant >1 g/ml). Five isolates (<1%) were resistant to levofloxacin. All isolates were susceptible to vancomycin. Mycobacterium 6% (27/427) were INH-resistant. Two cases of multidrug-resistant TB (resistant to at least INH and rifampin) were identified, tuberculosis both among foreign-born persons.